SCHEMBL5539148

SCHEMBL5539148

CC(C)(CO)CNC(=O)c1c(O)c2ncc(Cc3ccc(F)cc3F)cc2[nH]c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.38
GSK3B P49841 1/20 0.35
KDM5A P29375 2/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2B Q13224 1/20 0.34
TYK2 P29597 1/20 0.34
PDE4D Q08499 1/20 0.34
JAK2 O60674 2/20 0.34
PTGES O14684 1/20 0.33
KDM4E B2RXH2 2/20 0.33
GPER1 Q99527 1/20 0.33
NTRK1 P04629 1/20 0.32
IKBKE Q14164 1/20 0.32
AURKB Q96GD4 1/20 0.32
TBK1 Q9UHD2 1/20 0.32
ULK1 O75385 1/20 0.32
CDK1 P06493 1/20 0.32
CDK2 P24941 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546928 0.91 TDP1 (0.36) TDP1GSK3BKDM5AJAK2PTGES
SCHEMBL5548096 0.90 TDP1 (0.46) TDP1GSK3BKDM5AJAK2KDM4E
SCHEMBL16009913 0.87 PTGES (0.37) TDP1KDM5AGRIN1GRIN2BPTGES
SCHEMBL5545871 0.86 TDP1 (0.37) TDP1KDM5ATYK2PDE4DPTGES
SCHEMBL5545745 0.84 TDP1 (0.42) TDP1GSK3BKDM5AGRIN1GRIN2B
SCHEMBL5538581 0.79 KDM5A (0.46) KDM5APTGESKDM4EMEN1KMT2A
SCHEMBL5546798 0.79 GPR52 (0.38) TDP1GSK3BKDM5AMEN1KMT2A
SCHEMBL5538964 0.77 HDAC3 (0.36) TDP1GSK3BKDM5AKDM4EMEN1
SCHEMBL5546706 0.77 KDM4E (0.53) KDM4EKMT2A
SCHEMBL5546963 0.77 CNR2 (0.47) TDP1GSK3BKDM5AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 TDP1 801/4885GSK3B 2347/4885KDM5A 2056/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 TDP1 575/4885GSK3B 461/4885KDM5A 1439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.